TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02646202

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Injection of varices

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Band ligation
Description: endoscopic banding of varices

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scleroligation
Description: intra variceal endoscopic sclerotherapy combined with band ligation.
Study: NCT02685592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid nanoemulsion
Description: A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
Study: NCT04098640

Intervention type: GENETIC
Group type: OTHER
Intervention: FoundationOne CDx
Description: FoundationOne CDx will be performed using archival tumor tissue
Study: NCT00303628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT03986268

Intervention type: DRUG
Group type: OTHER
Intervention: Vit D
Description: The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
Study: NCT03632330

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Dexmedetomidine group
Study: NCT01811017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser
Study: NCT01634711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-C Ligament
Description: The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
Study: NCT03632330

Intervention type: DRUG
Intervention: Midazolam
Description: Midazolam group

Intervention type: DRUG
Intervention: Propofol
Description: Propofol group
Study: NCT02221895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum follow up appointment 2-3 weeks after delivery
Description: experimental arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postpartum follow up 6-8wk after delivery
Description: control arm
Study: NCT03213015

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle dorsiflexion measurement
Description: It was used the test with WB, called Lunge Test, in which each evaluator marked a point 15 cm distal to the anterior tuberosity of the tibia (TAT) with a felt tip pen. After that the smartphone (app iHand) will be placed at this point. Between each measurement, the mark was removed with alcohol 70% The demarcated point served as a guide for positioning the smartphone. In order to standardize the smartphone positioning, BHome (home button on the iPhone), was aligned with the TAT pen mark. To ensure the same distance from the foot to the test, the distance of the hallux to the wall was measured (tape measure), recorded and reused for each test.
Study: NCT01165346

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fiducials
Description: Implantation of fiducials

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: 3 fractions over 8 to 10 days, 15 Gy/fraction
Study: NCT03555578

Intervention type: DRUG
Intervention: Leuprorelin Acetate
Description: Leuprorelin Acetate Injection Kit
Study: NCT02689791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4
Description: single dose 26g fiber given at the breakfast meal
Study: NCT04274543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions.
Study: NCT02719847

Intervention type: PROCEDURE
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
Study: NCT03632330

Intervention type: DRUG
Intervention: Midazolam/Propofol
Description: Midazolam/Propofol group
Study: NCT02578797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
Study: NCT03067415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D565H(Latanoprost 25㎍/㎖)
Description: D565H twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D565H(Latanoprost 25㎍/㎖)
Description: D565H twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D565(Latanoprost 50㎍/㎖)
Description: D565 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D565(Latanoprost 50㎍/㎖)
Description: D565 once daily
Study: NCT02213536

Intervention type: RADIATION
Intervention: VMAT (Volumetric Modulated Arc Therapy)
Description: Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
Study: NCT03034928

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 1
Description: Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 1
Description: Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 1
Description: Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 1
Description: Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)

Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lens
Description: Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lens
Description: Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lens
Description: Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lens
Description: Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: OPTI-FREE® RepleniSH® MPDS
Description: Multipurpose contact lens solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OPTI-FREE® RepleniSH® MPDS
Description: Multipurpose contact lens solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OPTI-FREE® RepleniSH® MPDS
Description: Multipurpose contact lens solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OPTI-FREE® RepleniSH® MPDS
Description: Multipurpose contact lens solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 2
Description: Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 2
Description: Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 2
Description: Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 2
Description: Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
Study: NCT01449032

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC
Description: No of cells after culture expansion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3 cc saline
Study: NCT00221104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study: NCT01810952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine insulin
Description: In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine insulin
Description: In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Description: In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Description: In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH Insulin
Description: NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
Study: NCT04926233

Intervention type: DRUG
Intervention: Tiotropium bromide + Olodaterol
Description: Tiotropium bromide + Olodaterol

Intervention type: DRUG
Intervention: Tiotropium bromide + Olodaterol
Description: Tiotropium bromide + Olodaterol

Intervention type: DEVICE
Intervention: Sp(t)iolto® Respimat®
Description: Sp(t)iolto® Respimat®

Intervention type: DEVICE
Intervention: Sp(t)iolto® Respimat®
Description: Sp(t)iolto® Respimat®
Study: NCT04649307

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MI-CBT
Description: Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
Study: NCT03918200

Intervention type: OTHER
Intervention: Serum amyloid A level
Description: For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at -80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level

Intervention type: OTHER
Intervention: Serum amyloid A level
Description: For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at -80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level
Study: NCT00562328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Weeks 2-5:~375 mg/m\^2 by IV once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Week 1-6:~250 mcg subcutaneously three time as week
Study: NCT04242745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.
Study: NCT00164723

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsule endoscopy
Description: Capsule endoscopy and colonoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsule endoscopy
Description: Capsule endoscopy and colonoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsule endoscopy
Description: Capsule endoscopy and colonoscopy
Study: NCT01111669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (placebo)
Description: The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
Study: NCT03848468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: excision of 3rd and 4th degree hemorrhoids

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy
Description: excision of 3rd and 4th degree hemorrhoids
Study: NCT03869021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed surgical guide constructed
Description: A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin

Intervention type: OTHER
Group type: OTHER
Intervention: free hand surgery
Description: A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
Study: NCT04415905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The participants in the group P are anesthetized with propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The participants in the group S are anesthetized with sevoflurane.
Study: NCT02310347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronabinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01144806

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUTF
Description: Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
Study: NCT01766284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRIS 1300e
Description: Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
Study: NCT03415269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol Hydrochloride
Description: single lozenge of 20mg ambroxol
Study: NCT04055519

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Multi-purpose disinfection solution
Description: Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Multi-purpose disinfection solution
Description: Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
Study: NCT01939392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (OneShot™ Renal Denervation System)
Study: NCT03360968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable-PS
Description: Variable-PS mode switched on for 1 hour

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPN-CPAP/PS
Description: SPN-CPAP/PS mode switched on for 1 hour

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPN-CPAP/PS
Description: SPN-CPAP/PS mode switched on for 1 hour

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable-PS
Description: Variable-PS mode switched on for 1 hour
Study: NCT02298491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: 80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
Study: NCT03090295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palpation and Accuro
Description: Identify placement for spinal
Study: NCT01067547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose.
Description: The total dose of iron sucrose given will be individualised by calculating their iron deficit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: 300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
Study: NCT04153214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycling
Description: Participants will have a portable pedal machine under their desk and will use it 60minutes per day

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cycling
Description: Participants will have a portable pedal machine under their desk and will use it 60minutes per day
Study: NCT02639533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150 mg PO, single dose.
Study: NCT02699788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifunction Cardiogram
Study: NCT01781169

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplementation of vitamin D
Description: Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplementation of vitamin D
Description: Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
Study: NCT02376283

Intervention type: DRUG
Group type: OTHER
Intervention: Prasugrel

Intervention type: DRUG
Group type: OTHER
Intervention: Prasugrel

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel

Intervention type: DRUG
Group type: OTHER
Intervention: ticagrelor